Filing summary
Entity and period: The supplied filing is AVRA Medical Robotics, Inc.’s Form 10-Q for the quarter and nine months ended September 30, 2022, filed November 30, 2022. This does not match the request metadata identifying SS Innovations International, Inc. and 2022 Q1. The filing describes a medical robotics development-stage company; it reports no revenue.
Key financial results
| Metric | Three months ended September 30, 2022 | Nine months ended September 30, 2022 | Comparable 2021 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $900,145 | $1,150,631 | $418,238 and $1,130,667, respectively |
| Net loss, per financial statements | $790,104 | $1,040,525 | $418,209 and $1,130,578, respectively |
| Loss per share | $0.02 | $0.03 | $0.02 and $0.04, respectively |
| Cash and cash equivalents | $514,143 at September 30, 2022 | $405,774 at December 31, 2021 | |
| Total assets | $1,648,899 at September 30, 2022 | $428,607 at December 31, 2021 | |
| Current liabilities | $1,316,286 at September 30, 2022 | $287,281 at December 31, 2021 |
The filing does not report a meaningful revenue margin because there was no revenue. Cash used in operating activities was $303,712 for the nine months; investing activities used $1,100,000, principally for notes receivable; financing activities provided $1,512,080. The company reported $145,000 of related-party notes payable and $1,100,000 of promissory notes at quarter-end. No clear debt maturity schedule is provided for these balances in the financial statement summary.
Changes and notable items
- Quarterly net loss increased versus the prior-year quarter, while nine-month net loss decreased modestly on the face of the financial statements. Compensation expense was $724,965 for the quarter, up from $266,746; nine-month compensation expense was $819,732 versus $812,381.
- Cash increased by $108,368 from year-end. The company raised $250,000 in August 2022 through a restricted-share sale and received $412,080 in total proceeds from securities offerings during the nine-month period.
- The company issued substantial equity awards and options in July 2022. Stock-based compensation was a significant expense; the statement of cash flows reports $819,732 for the nine months.
- On August 5, 2022, AVRA entered into a non-binding letter of intent for a business combination with the SSI parties and advanced financing for the proposed transaction. On November 7, 2022, it entered into a definitive merger agreement. The proposed transaction would leave existing AVRA shareholders with 5% of post-merger common stock, subject to closing conditions and required corporate actions. The agreement also provides SSI- DE holders with preferred shares carrying 51% of total voting power.
- After quarter-end, the company reported selling 2,261,000 shares for $565,250 through the filing date.
Outlook, risks, and controls
Management describes plans to develop an AI-enabled medical robotics system, initially targeting aesthetic skin-resurfacing procedures. The filing provides no specific revenue, earnings, or cash-flow guidance. Commercialization depends on development, regulatory review, financing, and execution; claimed timing and regulatory advantages are management expectations, not established outcomes.
- Going concern: The company has no established revenue stream sufficient to cover operating costs and depends on debt and equity financing. Management states that substantial doubt exists about its ability to continue as a going concern and that additional financing is not assured.
- Transaction uncertainty: The merger remains subject to closing conditions, including a name change, a 1-for-10 reverse stock split, and an increase in authorized common shares, as well as regulatory and corporate filings.
- Liquidity and dilution: The filing warns that failure to obtain financing could require curtailed operations or strategic alternatives; further financing may substantially dilute existing holders.
- Disclosure controls: Management concluded disclosure controls and procedures were not effective at the reasonable-assurance level because of material weaknesses previously identified.
- Other exposure: The company states that $238,446 of cash exceeded the FDIC insurance limit at September 30, 2022. It reports no material off-balance-sheet arrangements and no legal proceedings.
Investor verification priorities
- Confirm the correct issuer and reporting period: the supplied filing is AVRA’s September 2022 Form 10-Q, not an SS Innovations International, Inc. 2022 Q1 filing.
- Reconcile reported losses: the statements show quarterly net loss of $790,104 and nine-month net loss of $1,040,525, while MD&A gives different figures in places. The MD&A also describes quarterly expenses and loss inconsistently.
- Reconcile balance-sheet and going-concern disclosures: the balance sheet shows total assets of $1,648,899, liabilities of $1,316,286, and positive stockholders’ equity of $332,613, while the notes cite a stockholders’ deficit of $222,724. The MD&A also presents different asset and liability totals.
- Verify the amount and accounting for transaction financing: the filing describes $2.25 million of interim financing, lists four notes totaling $2.5 million, and reports $1.1 million each of notes receivable and promissory notes on the balance sheet.
- Assess merger closing conditions, post-merger voting control, dilution, and the status and terms of any additional financing.